Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other …

Jan 14, 2025 · BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

The Investor Relations website contains information about BioNTech's business for stockholders, potential investors, and financial analysts.

Sep 17, 2024 · The Investor Relations website contains information about BioNTech's business for stockholders, potential investors, and financial analysts.

MAINZ, GERMANY, October 1, 2021(GLOBE NEWSWIRE) – BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial.

MAINZ, Germany, October 19, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that the first patient has been treated in a Phase 2 clinical trial evaluating the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457 ...

MAINZ, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced positive topline data from the ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899) in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD- (L)1 ...

May 21, 2024 · BioNTech will present an analysis of real-world data that investigated the overall survival, treatment patterns and prognostic variables of patients with testicular germ cell tumors receiving palliative chemotherapy.

Nov 4, 2024 · The Investor Relations website contains information about BioNTech's business for stockholders, potential investors, and financial analysts.

Apr 3, 2023 · BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers